Plant Infrastructure
Product delivery and quality assurance are critical business functions that MAXHEAL executes in strict compliance with industry and regulatory requirements. MAXHEAL’s quality systems encompass validation, change control, production support, documentation control, and other cGMP services, ensuring excellence at both the plant and customer levels.
Dedicated Betalactum Plant
Nashik, an industrial hub of Maharashtra, is at about 180Km (112 Miles) from Mumbai and well connected by road and rail transport. It is the location of Maxheal Group’s flagship company Maxheal Pharmaceuticals (India) Ltd an Dedicated Penicillin EU-GMP plant. Started as a small scale unit with bare minimum manufacturing facilities, is today one of the fastest growing pharmaceutical company in the region.
| Product | Daily Production Capacity |
| Tablets | 9.0 Lac Tablet/Shift |
| Capsules | 11.0 Lac Capsules/Shift |
| Dry Syrup | 20,000 Bottles/Shift |
| TOTAL SITE AREA | 2788 Sq Mt. |
| TOTAL CONSTRUCTED AREA | 2300 Sq Mt. |
| QC & QA AREA | 175 Sq Mt. |
| FACILITIES | Tablets, Capsules, Dry Syrup, β- Lactum, Cephalosporins |
| EMPLOYEE STRENGTH | 200 to 250 |
| FACILITIES PLANNED | Veterinary Tablets |
| ANNUAL MANUFACTURING CAPACITY | Tablets - 750 million Capsules (β - Lactum & General) - 900 million Dry syrup - 5.4 million |
| ACCREDITATION'S | WHO-cGMP, NAFDAC, FDB-Ghana, Ethiopia MOH, Burkina Faso, Sierra Leone, EU-GMP |
Future planned Cephalosporins Plant
MAXHEAL acquired a pre-existing manufacturing unit at Boisar, an industrial zone in Maharashtra, situated 100 km from Mumbai. Ally Pharma Options Pvt. Ltd., a WHO-cGMP-certified unit, holds approvals from NAFDAC, FDB (Ghana), Kenya, and Uganda. Its infrastructure is par excellence and compatible with international standards.
Spread over 45,000 sq. ft. of land, the unit also features ample free space for future expansion, which is an added advantage.
| Product | Daily Production Capacity |
| Tablets | |
| Capsules | |
| Liquid Oral | |
| Ointment | |
| Dry Syrup |
| TOTAL SITE AREA | 8361 Sq Mt. |
| TOTAL CONSTRUCTED AREA | 4089 Sq Mt. |
| QC & QA AREA | 250 Sq Mt. |
| AREA FOR EXPANSION | 4022 Sq Mt. |
| FACILITIES | Tablets, Capsules, Liquid-Oral, Ointment, Dry Syrup, Pellets formation |
| EMPLOYEE STRENGTH | 125 to 150 |
| FACILITIES PLANNED | β- Lactum Unit, Sterile Ointment |
| ANNUAL MANUFACTURING CAPACITY | Tablets 60 million, Capsules 67.2 million, Bottles 19 million, Tubes 10 million |
| ACCREDITATION'S | WHO-cGMP, NAFDAC, FDB-Ghana, Food and Poison Board-Kenya, NDA-Uganda |
- Formulation and Development
- Strong Micro Department
- Injectables
MAXHEAL introduced a third operational unit, viz. MAXHEAL Laboratories Pvt. Ltd., at the Special Economic Zone (SEZ) in Sachin, near Surat. This site is equipped with EU-GMP, WHO-GMP, NAFDAC, FDB (Ghana), and Ethiopia-approved facilities. Its infrastructure is par excellence, compatible with UK-MHRA standards, and a team of equally qualified personnel adds another feather to MAXHEAL’s cap.
The plant is well-connected by rail, road, and air transport and is located approximately 271 km from Mumbai.
| Product | Daily Production Capacity |
| Tablets | 20,00,000 No./Shift |
| Capsules | 10,00,000 No./Shift |
| Dry Syrup | 10,000 Bottels/Shift |
| Svp-Ampules | 1,00,000 No./Shift |
| Svp-Vials-10ml | 40,000 No./Shift |
| Svp-Eyedrops | 20,000 No./Shift |
| Dry powder Inj | 40,000 No./Shift |
| Sachets | 40,000 No./Shift |
| TOTAL SITE AREA | 14,400 Sq Mt. |
| TOTAL CONSTRUCTED AREA | 14,400 Sq Mt. - 2 Storey building |
| QC & QA AREA | 850 Sq Mt |
| AREA AVAILABLE FOR EXPANSION | 5100 Sq Mt. |
| FACILITIES | Tablets, Capsules |
| EMPLOYEE STRENGTH | 225 to 250 |
| FACILITIES PLANNED | Injectables, Oral Rehydration Salt, Dry Powder |
| ANNUAL MANUFACTURING CAPACITY | Tablets 1000 million. Capsules 750 million |
| PROJECTED MANUFACTURING CAPACITY | Tablets 1000 million, Capsules 750 million |
| ACCREDITATION'S | WHO-cGMP, NAFDAC, FDB-Ghana |